MedTrace Logo

Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers

NCT05647343 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-07-24

No results posted yet for this study

Summary

The goal of this clinical trial is to assess the safety, tolerability and pharmacokinetics of ATL-001 (ciclopirox olamine) in healthy volunteers

Conditions

  • Adverse Effect of Drugs and Medicaments in Therapeutic Use

Interventions

DRUG

Ciclopirox Olamine Oral

On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

OTHER

Placebo

On the morning of Day 1 to Day 5, each participant will receive a single oral dose of ATL-001 or placebo

Sponsors & Collaborators

  • Atlas Molecular Pharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-31
Primary Completion
2024-04-08
Completion
2024-04-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05647343 on ClinicalTrials.gov